Press Release Depot

LEIDEN, Netherlands and PARSIPPANY, N.J., June 25 /PRNewswire/ — DSM
Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX)
announced today that they have entered into an agreement with Avid
Bioservices, Inc. of Tustin, California to join their Vendor Network. Under
the terms of the agreement, Avid will be a pre-approved contract manufacturer
(CMO) for licensees of the PER.C6(R) cell line located in the western U.S.
Avid is the first U.S.-based contract manufacturer to be awarded this status.

Karen King, president of DSM Biologics notes, “We are confident that
Avid’s excellent reputation and service level will be instrumental in making
the PER.C6(R) technology available to licensees on the West Coast, bringing
our technology to a wider regional base as we continue to grow globally.”

Steven W. King, president of Avid Bioservices added, “We are honored to
achieve the distinction of being the first pre-approved U.S.-based CMO to
manufacture proteins and antibodies using the PER.C6(R) cell line. The
PER.C6(R) technology is recognized throughout our industry as providing
important advantages compared to other platforms, including serum-free medium,
scalability and high productivity levels making the system an ideal fit for
Avid.”

Crucell and DSM last week announced a breakthrough in the production of
IgG antibodies using Crucell’s PER.C6(R) technology. By employing the
PER.C6(R) human cell line and DSM’s proprietary XD(TM) technology, a record
yield of over 27 grams per liter has been achieved.

The PER.C6(R) technology platform has been developed for the large-scale
manufacture of biopharmaceutical products such as recombinant proteins,
including monoclonal antibodies. Compared to conventional production
technologies, the strengths of PER.C6(R) technology lie in its excellent
safety profile, scalability and productivity under serum-free culture
conditions.

Other terms of the agreement were not disclosed. Avid Bioservices is a
wholly owned subsidiary of Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM).

About PER.C6(R) technology

Crucell’s PER.C6(R) technology platform has been developed for the
large-scale manufacture of biopharmaceutical products such as recombinant
proteins including monoclonal antibodies. Compared to conventional production
technologies, the strengths of PER.C6(R) technology lie in its excellent
safety profile, scalability and productivity under serum-free culture
conditions.

About XD(TM) technology

DSM’s XD(TM) technology has been developed as a proprietary system to
drive yield improvements in mammalian systems. “XD” stands for extreme
density, as the process is able to push the cell density within the bioreactor
to maximum productivity.

About Avid Bioservices, Inc.

Avid Bioservices provides a comprehensive range of cGMP manufacturing
services for the biotechnology and biopharmaceutical industries. Avid
manufactures cGMP commercial product, as well as clinical supplies for all
phases of clinical trials. The company’s comprehensive range of cGMP services
includes cell banking, stability testing, clinical product manufacturing and
purification, bulk packaging, final product filling and regulatory support.
Avid also provides a variety of process development activities, including cell
line optimization, analytical method development and product characterization.
Avid has over 10 years of antibody manufacturing experience producing
monoclonal antibodies and recombinant proteins in batch, fed-batch and
perfusion modes. For more information about Avid, visit www.avidbio.com.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative product candidates in clinical trials for the
treatment of cancer and hepatitis C virus (HCV) infection. The company is
pursuing three separate clinical programs in cancer and HCV infection with its
lead product candidates bavituximab and Cotara(R). Peregrine also has
in-house manufacturing capabilities through its wholly owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
bio-manufacturing services for both Peregrine and outside customers.
Additional information about Peregrine can be found at www.peregrineinc.com.

About Crucell

Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) is a global
biopharma company focused on research, development, production and marketing
of vaccines, proteins and antibodies that prevent and treat primarily
infectious diseases. Its vaccines are sold in public and private markets
worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B, a
fully-liquid vaccine against five important childhood diseases and a
virosome-adjuvanted vaccine against influenza. Crucell also markets travel
vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine
and the only aluminum-free hepatitis A vaccine on the market. The Company has
a broad development pipeline, with several product candidates based on its
unique PER.C6(R) production technology. The Company licenses its PER.C6(R)
technology and other technologies to the biopharmaceutical industry.
Important partners and licensees include DSM Biologics, sanofi-aventis,
Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the
Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and
the U.S. The Company employs over 1000 people. For more information, please
visit www.crucell.com.

About DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global
provider of manufacturing technology & services to the biopharmaceutical
industry. In addition to offering world-class biopharmaceutical manufacturing
services, DSM Biologics has co-exclusive rights, along with Dutch biotech
company Crucell N.V., to license the high-producing PER.C6(R) human cell line
as a production platform for recombinant proteins and monoclonal antibodies.
The combination of the PER.C6(R) human cell line and DSM’s manufacturing
services provides companies with a turn-key biologic manufacturing solution
reducing cost, risk and time to market.

DSM — the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences
and Materials Sciences that contribute to the quality of life. DSM’s products
and services are used globally in a wide range of markets and applications,
supporting a healthier, more sustainable and more enjoyable way of life. End
markets include human and animal nutrition and health, personal care,
pharmaceuticals, automotive, coatings and paint, electrics and electronics,
life protection and housing. DSM has annual sales of almost EUR 8.8 billion
and employs some 23,000 people worldwide. The company is headquartered in the
Netherlands, with locations on five continents. DSM is listed on Euronext
Amsterdam. More information: www.dsm.com.

DSM Forward-looking statements

This press release contains forward-looking statements that involve
inherent risks and uncertainties. These statements are based on current
expectations, estimates and projections of the management of DSM and Crucell
and information currently available to both companies. The statements involve
certain risks and uncertainties that are difficult to predict and therefore
DSM and Crucell do not guarantee that their expectations will be realized.
Furthermore, DSM and Crucell have no obligation to update the statements
contained in this press release.

Crucell N.V. has identified certain important factors that may cause
actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors please
refer to the Form 20-F, as filed by Crucell N.V. with the U.S. Securities and
Exchange Commission on May 7, 2008, and in particular the section entitled
“Risk Factors”. Crucell N.V. prepares its financial statements under
International Financial Reporting Standards (IFRS).

SOURCE DSM Pharmaceutical Products

OAKLAND, Calif., May 1 /PRNewswire-USNewswire/ — With talk of a new
effort to enact healthcare reform surfacing in Sacramento, a new field poll
this week illustrates that Californians will once again pay particular
attention to the voice of the California Nurses Association and registered
nurses.

A poll this week by the influential Field Institute released documented
that CNA had the highest favorable rating of all the groups, politicians, and
institutions engaged in the healthcare debate that dominated much of the
state’s public policy debate over the past year.

The public gave CNA and nurses an overall approval rating of 53 per cent
and a disapproval rating of just 15 percent, for a net of 38 percent — in
sharp contrast to other central figures in the healthcare policy
fight — particularly the health insurance industry which scored an abysmal 55
percent negative rating.

Favorable Unfavorable Net
difference
California Nurses Association/
Nurses 53% 15% +35%
California Hospital Assn./
Hospitals 33% 30% +3%
Gov. Arnold Schwarzenegger 40% 40% 0
Assembly Speaker Fabian Nunez 20% 29% -8%
Chamber of Commerce/
Business Groups 25% 36% -11%
News Media 28% 46% -18%
Republican State
Legislative Leaders 22% 48% -26%
Health Insurance Companies 16% 55% -39%

CNA and its national affiliate, the National Nurses Organizing Committee,
have gained increasing recognition as a national leader in the battle for
comprehensive, universal, guaranteed healthcare for all through a single-payer
or Medicare-for-all type system.

In California, CNA is the principle sponsor of SB 840, a bill by Sen.
Sheila Kuehl, to achieve that goal, and national legislation, HR 676, by Rep.
John Conyers, which has more cosponsors than any other national healthcare
bill.

CNA/NNOC is also well known for its assertive challenge to the insurance
industry and spirited campaigns to demand insurers provide care to individual
patients denied needed medical treatment recommended by their physicians, as
in the nationally prominent cases of Nataline Sarkisyan and Nick Colombo.

“We are honored that CNA and nurses are held in such high esteem by
Californians,” said Malinda Markowitz, RN, member of the CNA/National Nurses
Organizing Committee’s Council of Presidents.

“CNA and RNs have an unflagging commitment to public safety and assuring
enactment of comprehensive, genuine healthcare reform that ends the growing
crisis our patients and our communities face daily. What the public seems to
know is that we refuse to be compromised by narrow interests or approaches
that reward the insurance industry at the expense of public safety, and
guaranteed quality healthcare for all,” she said.

CNA and RNs, Markowitz added, “will never cease our fight for genuine
reform.” This year, CNA/NNOC will continue to urge action on SB 840, a
Medicare-for-all style reform, sponsored by State Sen. Sheila Kuehl.

In the interim, CNA/NNOC is actively campaigning for SB 1459 by State Sen.
Leland Yee that would expand access to existing public health programs for
200,000 uninsured children and 170,000 adults.

The Field Poll demonstrated the growing concern of Californians for
genuine reform with more Californians than ever worried about losing coverage,
having their policies cancelled when they are sick, or being unable to afford
care.

Further, the poll showed the number of Californians favoring
government-provided care growing, findings that resonate with numerous
national surveys. For example, a March 2007 New York Times/CBS News Poll
found that that 64 per cent of Americans believe the government should
guarantee health coverage to all.

A December 2007 Associated Press/Yahoo poll found 65 percent of those
polled said the United States should adopt universal health insurance that
covers everyone under a program such as Medicare that is run by the government
and financed by taxpayers. And 54 percent went where politicians dare not
tread, saying they supported a “single-payer” health system whereby all
Americans would get their health coverage from a single government plan
financed by taxpayers.

SOURCE California Nurses Association

SHANGHAI, China, April 15 /Xinhua-PRNewswire-FirstCall/ — Linkwell
Corporation (Linkwell or the Company) (OTC Bulletin Board: LWLL), a leading
developer, manufacturer and distributor of healthcare related disinfectants
in China, announced today: financial results for the fiscal year ended
December 31, 2007 and provided guidance for 1st quarter 2008 and the entire
year 2008.

Net revenues for the fiscal year ended December 31, 2007 increased
$6,590,343, or approximately 85%, to $14,335,721, compared with $7,745,378 for
the fiscal year ended December 31, 2006. Net revenues for the Company’s
subsidiary LiKang Disinfectant were $8,127,717 and $6,208,004 for its
subsidiary Shanghai LiKang International Trade Company Trade Co., Ltd (LiKang
International).

The majority of the increase in net revenues was attributable to its
subsidiary LiKang International, whose net revenues for the fiscal year ended
2007 increased approximately 761%, or $6,208,004 as compared to $720,996 for
the fiscal year ended 2006, an increase of $5,487,008.

Net revenues for Linkwell’s subsidiary LiKang Disinfectant increased
approximately 16%, or $1,103,335 to $8,127,717 or for year end 2007. The
Company believes this increase in demand was due to an increase in its sales
staff and customer recognition of the Company’s high-quality, competitively
priced disinfectant products.

Total operating expenses for 2007 were $3,852,398, which was an increase
of $1,548,905, or approximately 67%, from year end 2006 of $2,303,493. This
increase is primarily attributable to an increase in general and
administrative expenses, most of which was the result of a one-time write off
of $564,000 due to terminating a contract with China Direct Investments, Inc.,
which were expensed for the year ended December 31, 2007. A second cause of
increasing operating expenses was due to building out its sales and service
division to improve future growth.

Linkwell reported net income of $360,135 for the fiscal year ended
December 31, 2007, as compared to net income of $568,120 for the fiscal year
ended December 31, 2006. However, the net income for Linkwell’s subsidiary,
LiKang Disinfectant, increased approximately 3%, with net income of $1,196,318
for 2007 compared to $1,161,828 for 2006.

The primary causes for the decrease in net income for the year ended 2007
were attributable to four key factors: (1) the increase in cost of sales;
(2) the low net income of our subsidiary LiKang International; (3) the
increase in doubtful accounts of $448,958; and (4) a one-time write off of
$564,000 as a result of terminating our contract with China Direct Investments,
Inc.

LINKWELL CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
December 31,
ASSETS
2007 2006
CURRENT ASSETS:

Cash $1,222,128 $1,713,723
Accounts receivable (net of allowance for
doubtful accounts of $460,175 and
$144,639 in 2007 and 2006 respectively) 2,999,191 1,682,878
Accounts receivable-related parties
(net of allowance for doubtful accounts
of $221,359 and $87,937 in
2007 and 2006 respectively) 1,992,233 1,406,425
Other receivable 261,231 414,000
Inventories (net of reserve for obsolete
inventory of $136,287 and $127,160 in
2007 and 2006 respectively) 829,476 536,483
Prepaid expenses and other current assets 1,015,558 367,641
Due from related parties 946,591 –
Short term loan receivable — 48,609

Total Current Assets 9,266,408 6,169,759

PROPERTY AND EQUIPMENT - net 749,073 774,733

Total Assets $10,015,481 $6,944,492

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:
Loans payable $699,210 $652,382
Loan payable - related party — 165,471
Accounts payable and accrued expenses 1,246,943 1,301,131
Tax payable 92,815 –
Other payable 189,421 27,589
Due to related party 760,457 204,267
Advances from customers 713,578 254,434
Total Current Liabilities 3,702,424 2,605,274

MINORITY INTEREST 527,244 394,320

STOCKHOLDERS’ EQUITY:
Preferred stock (No Par Value;
10,000,000 Shares Authorized;
No shares issued and outstanding)
Common Stock ($0.0005 Par Value; 150,000,000
Shares Authorized; 73,731,675 and
69,868,355 shares issued and outstanding in
2007 and 2006 respectively) 36,866 34,934
Common stock issuable 11 –
Additional paid-in capital 5,724,363 5,290,536
Accumulated deficit (510,921) (871,056)
Deferred compensation (51,389) (646,222)
Other comprehensive gain - foreign currency 586,883 136,706

Total Stockholders’ Equity 5,785,813 3,944,898

Total Liabilities and Stockholders’
Equity $10,015,481 $6,944,492

LINKWELL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

For the Year
Ended December 31,
2007 2006
NET REVENUES
Non-affiliated companies $11,694,030 $4,508,179
Affiliated companies 2,641,691 3,237,199

Total Net Revenues 14,335,721 7,745,378

COST OF SALES 10,071,991 4,609,557

GROSS PROFIT 4,263,730 3,135,821

OPERATING EXPENSES:
Selling expenses 1,099,266 573,315
General and administrative 2,753,132 1,730,178

Total Operating Expenses 3,852,398 2,303,493

INCOME FROM OPERATIONS 411,332 832,328

OTHER INCOME (EXPENSE):
Other income 146,945 (4,367)
Registration rights penalty — (76,000)
Interest income 3,649 5,441
Interest expense - related party — (26,132)
Interest expense (68,867) (41,589)

Total Other Income (Expense) 81,727 (142,647)

INCOME BEFORE DISCONTINUED OPERATIONS,
INCOME TAXES AND MINORITY INTEREST 493,059 689,681

DISCONTINUED OPERATIONS:
Gain from discontinued operations — 12,794

INCOME BEFORE INCOME TAXES
AND MINORITY INTEREST 493,059 702,475

INCOME TAXES — (1,318)

INCOME BEFORE MINORITY INTEREST 493,059 701,157

MINORITY INTEREST (132,924) (133,037)

NET INCOME $360,135 $568,120

CUMULATIVE PREFERRED DIVIDENDS — (96,240)

NET INCOME ATTRIBUTABLE
TO COMMON SHAREHOLDERS $360,135 $471,880

BASIC AND DILUTED INCOME PER COMMON SHARE:
Basic earnings per share from
continued operation $0.00 $0.01
Basic earnings per share including
discontinued operation $0.00 $0.01
Diluted earnings per share from
continued operation $0.00 $0.01
Diluted earnings per share including
discontinued operation $0.00 $0.01

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic 73,195,593 53,098,047
Diluted 73,455,345 57,539,614

LINKWELL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Years
Ended December 31,
2007 2006
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $360,135 $568,120
(Gain) Loss from discontinued operations — (12,794)
Income from continuing operations 360,135 555,326

Adjustments to reconcile net income from
operations to net cash provided by
(used in) operating activities:
Depreciation and amortization 126,295 91,657
Minority interest 132,924 145,150
Allowance for doubtful accounts 315,536 131,296
Allowance for doubtful accounts-related
party 133,422 87,937
Stock-based compensation 709,271 398,945
Changes in assets and liabilities:
Accounts receivable (1,631,849) (361,386)
Accounts receivable - related party (719,230) (621,992)
Other receivable 152,769 (414,000)
Inventories (292,993) 431,741
Prepaid and other current assets (647,917) (285,891)
Other assets — 734
Accounts payable and accrued expenses 107,644 (71,984)
Tax payable 92,815 (75,489)
Advances from customers 459,144 123,516

NET CASH (USED IN) PROVIDED BY OPERATING
ACTIVITIES (702,034) 135,560

CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in loan receivable 48,609 (48,609)
Increase in loan receivable - related
party (946,591) –
Increase in deposit on investment — 100,000
Purchase of property, plant and
equipment (99,349) (149,339)

NET CASH USED IN INVESTING ACTIVITIES (997,331) (97,948)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from loans payable 699,210 63,157
Proceeds from loans payable-related
party 556,190 204,267
Repayment of loan payable (699,210)
Repayment of loan payable - related
party (165,471) (63,157)
Proceeds from Warrants Exercised 321,332 –

NET CASH PROVIDED BY FINANCING ACTIVITIES 712,051 204,267

EFFECT OF EXCHANGE RATE ON CASH 495,719 11,766

NET (DECREASE) INCREASE IN CASH (491,595) 253,645

CASH - beginning of year 1,713,723 1,460,078

CASH - end of year $1,222,128 $1,713,723

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for:
Interest $68,867 $67,721
Income taxes $– $1,318

Financial Projections for the first quarter 2008 (in 000s)

1st Qtr 2008
Estimate 1st Qtr 2007 Change

Total Revenues $3,814 $2,846 + 34%
Gross Profit $1,489 $993 + 50%
Net Income $400 $497 - 19.5%

Guidance for the first quarter 2008

“We believe our anticipated increase in revenues and gross profit for 1st
quarter 2008 compared to 2007 validates our recently implemented growth
strategy,” commented Linkwell Chairman and CEO, Mr. Xuelian Bian, “Our
projected total revenue growth of 34% in 1st quarter continues at a strong
pace in what is historically our weakest quarter, plus this year we had to
deal with a horrible winter storm.” Management estimates that while LiKang
Disinfectant’s revenues and net income increased slightly, LiKang
International’s revenues rose substantially, but its profits decreased.

Financial Projections for the full year 2008 (in 000s)

12/31/2008
Estimate 12/31/ 2007 Change

Total Revenues $23,180 $14,335 + 62%
Gross Profit $7,000 $4,767 + 47%
Net Income $2,000 $360 + 455%

Projected Net Revenues for the full year 2008

Linkwell’s management believes that financial projections for 2008 are
conservative, based on reasonable direct growth and cost estimates. However,
the Company has set higher goals for itself than projected, which are based on
anticipated indirect benefits from potential developments based on support to
the Beijing Olympics; introduction of new products to the market; management’s
increasing prestige and influence in the disinfectant industry; and strategic
ventures or agreements.

For the full year 2008, Linkwell projects total revenue to grow
approximately 62% to $23.2 million from $14.3 million in 2007. Specifically,
estimated revenue from LiKang Disinfectant is expected to rise approximately
$3.95 million or 49%, to $12.05 million in 2008, compared to $8.1 million in
2007. Also, management estimates that revenue from LiKang International will
increase approximately 15%, to $7.13 million in 2008, compared to $6.2 million
in 2007.

Of the estimated $3.95 million increase in total revenue from LiKang
Disinfectant in 2008, the Company estimates $10.25 million will come from
sales of current and new products; $0.5 million from training disinfection and
pest control professionals and sales of An’erdian at the 2008 Beijing Olympic
Games; $0.3 million from implementing China’s new disinfection vocational
training and licensing program; and $1.0 million from Ecolab related
agreements.

In addition, Linkwell anticipates revenues of $4.0 million in 2008 from
strategic acquisitions as part of the disinfectant industry’s consolidation in
China.

Chairman and CEO’s Comments on Guidance for the full year 2008

“In general for 2008, we expect stronger demand for our products due to
increased marketing and branding and from our associations with the Beijing
Olympic Games and Ecolab. We are making good progress on our 10 new products
in various stages of development and are on track to launch 3 new products
this year. We also believe that government administered health facilities and
the general public will increase consumption of our products due to increased
health education of the importance of disinfection and continued awareness of
health dangers, such as highly pathogenic bird flu, hepatitis, sexually
transmitted diseases and other potentially epidemic and pandemic outbreaks.”

Our vision for Linkwell is to be the consolidation leader of the estimated
$6.25 billion disinfectant industry in China. We believe China is on the
leading edge of a massive consolidation from over 1000 small disinfectant
manufacturing companies now, to less than 200 in the next five years.
Regarding our continued market penetration and the condition of our
competition, we believe the factors previously described, increases barriers
to entry and puts us in a very good position to lead consolidation of the
disinfectant industry.”

“Last, but certainly not least, we believe good corporate governance
measures and practices are very important to Linkwell and our investors. I am
dedicated to implementing and maintaining these measures as described in
appropriate SEC and stock exchange rules and regulations, including the
establishment of an independent board of directors, hiring a qualified CFO,
and reliable disclosure and internal control procedures.”

About Linkwell Corporation

Linkwell develops, manufactures and distributes disinfectant healthcare
products in China through its subsidiary LiKang Disinfectant. Linkwell’s
disinfectant healthcare products are a nationally recognized domestic Chinese
brand in this market segment. Linkwell products include disinfectants in
liquid, tablet, powder and aerosol form. Through LiKang, Linkwell has a
national marketing and sales presence throughout all 22 provinces,
5 autonomous regions, and 4 special municipalities of China. For more
information, please visit http://www.linkwell.us .

Safe Harbor Statement

This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. These forward-
looking statements are based on current expectations or beliefs, including,
but not limited to, statements concerning the Company’s operations, financial
performance and condition. For this purpose, statements that are not
statements of historical fact may be deemed to be forward-looking statements.
The Company cautions that these statements by their nature involve risks and
uncertainties, and actual results may differ materially depending on a variety
of important factors, including, but not limited to, the impact of competitive
products; pricing and new technology; changes in consumer preferences and
tastes; effectiveness of marketing; changes in laws and regulations;
fluctuations in costs of production; and other factors as those discussed in
the Company’s reports filed with the Securities and Exchange Commission from
time to time. In addition, the Company disclaims any obligation to update any
forward-looking statements to reflect events or circumstances after the date
hereof.

For more information, please contact:

Investor Relations
Craig Bird
Segue Ventures LLC
Tel: +1-215-885-4981
Email: chbird@segue.biz

SOURCE Linkwell Corporation

NEW YORK, March 4 /PRNewswire/ — Healthcare professionals who use
Advanstar’s ModernMedicine.com will experience enhanced Web search results as
a result of a newly announced strategic partnership with SearchMedica.com, the
medical professional’s search engine. ModernMedicine.com is an innovative,
online clinical decision-support resource.

“SearchMedica is proud to supplement ModernMedicine.com in its effort to
provide quality, credible healthcare information to medical professionals,”
said Cyndy Finnie, senior product manager for SearchMedica. “SearchMedica is
committed to connecting physicians and other healthcare professionals to these
trusted resources, ultimately improving patient care.”

As part of this strategic partnership, SearchMedica.com will power
ModernMedicine’s Web searches, driving reliable medical search results to the
ModernMedicine.com search results page. In turn, ModernMedicine.com will offer
users access to credible professional medical search results on
SearchMedica.com.

“ModernMedicine.com provides healthcare professionals with instant answers
to clinical and practice management questions from highly credible and trusted
sources,” said David Hoo, vice president of marketing for Advanstar Life
Sciences Marketing. “The partnership with SearchMedica enhances our content
and features and fits with our new digital strategy to bring timely, high
quality content to the medical community aggregated from strategic partners as
well as our own brands.”

ModernMedicine provides healthcare professionals with access to a robust,
cross-specialty library of content that is complemented by interactive tools
and features. The beta version registered more than 25,000 users in 2007 with
minimal promotion. As of February 29, 2008, registration had surpassed 50,000,
and the site is now being further expanded with a goal of registering
150,000 users or more.

In addition to ranking search results according to relevance as many
search engines do, SearchMedica also organizes results into such categories as
practical articles and news, research reviews and editorials, evidence-based
articles and meta-analyses, practice guidelines, clinical trials for patients,
continuing medical education, and alternative or complementary medicine. This
segmented organization makes it easier than ever for healthcare professionals
to pinpoint the information they seek.

About SearchMedica.com:

SearchMedica.com indexes only authoritative medical information, approved
for inclusion by medical editors and a physician editorial board. Medical
professionals receive more relevant, smaller sets of search results from
SearchMedica.com than from mainstream engines, which contain
consumer-oriented, paid testimonials and other types of unreliable
information. Since SearchMedica.com is advertiser supported, medical
professionals pay nothing to use the specialty search engine. All SearchMedica
search results are independent and unbiased. They contain well-known, credible
journals, peer-reviewed research, and evidence-based articles written for
practicing healthcare professionals. SearchMedica is currently available at
http://www.SearchMedica.com.

About ModernMedicine.com:

ModernMedicine.com (http://www.modernmedicine.com) is an online service of
Advanstar Communications Inc. (http://www.advanstar.com), a leading worldwide
media company providing integrated marketing solutions for the Fashion, Life
Sciences and Powersports industries. Advanstar serves business professionals
and consumers in these industries with its portfolio of 47 events,
60 publications and directories, 95 electronic publications and Web sites, as
well as educational and direct marketing products and services. Market leading
brands and a commitment to delivering innovative, quality products and
services enables Advanstar to “Connect Our Customers With Theirs.” Advanstar
has approximately 1,000 employees and currently operates from multiple offices
in North America and Europe.

SOURCE SearchMedica.com